Chaitali Nangia, MD, Patty and George Hoag Cancer Center
Articles by Chaitali Nangia, MD, Patty and George Hoag Cancer Center
Looking Toward the Future Management of Non–Small Cell Lung Cancer
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.
Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.
Novel Therapy for NSCLC With ALK Rearrangements
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.
Novel Therapy for NSCLC With KRAS G12C Mutation
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jonathan Riess, MD,Jessica Donington, MD, MSCR,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.
Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Heather Wakelee, MD,Alexander Spira, MD, PhD, FACP Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.
Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jonathan Riess, MD,Jessica Donington, MD, MSCR,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.
Selecting Therapy for Advanced NSCLC With EGFR Mutations
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather Wakelee, MD Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.
Neoadjuvant Strategies in Resectable Non–Small Cell Lung Cancer
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee, MD, FASCO Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.
Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS Trials
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.
Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice
Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.
Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.
Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee, MD, FASCO Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.
Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee, MD, FASCO A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.
Real-World Data and Barriers to Use of Molecular Testing in NSCLC
ByBenjamin P. Levy, MD,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Heather A. Wakelee, MD, FASCO A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.
Optimal Molecular Testing Practices in Non–Small Cell Lung Cancer
ByBenjamin P. Levy, MD,Jessica Donington, MD, MSCR,Jonathan Riess, MD,Alexander Spira, MD, PhD, FACP,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Heather A. Wakelee, MD, FASCO Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.
Immunotherapy for NSCLC: Clinical Pearls
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.
Blood-Based Biomarkers in NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.
Perioperative Approaches to NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center,Martin Dietrich, MD, PhD Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.
Biomarkers for Immunotherapy in Resectable NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.
Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.
Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Neal Edward Ready, MD, PhD, Duke Medical Center,Sandip P. Patel, MD, University of California San Diego The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.
Neoadjuvant Immunotherapy for Resectable NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.
CRT and I-O for Unresectable Stage III NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.
Appropriateness for Durvalumab in Unresectable Stage III NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.
Risks of Pneumonitis in Unresectable Stage III NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.
Durvalumab for Unresectable Stage III NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.
Second-Line Therapy for Stage IV NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.
Frontline Treatment of Stage IV NSCLC: What’s Next?
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Future projections regarding the role of novel I-O therapies as frontline treatment for patients with metastatic non–small cell lung cancer.
Immune-Related Adverse Events in NSCLC
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center Recommendations for managing immune-related adverse events associated with checkpoint inhibitors used to treat stage IV non–small cell lung cancer.
Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation
Neoadjuvant Strategies in Resectable Non–Small Cell Lung Cancer
Novel Therapy for NSCLC With ALK Rearrangements
Appropriateness for Durvalumab in Unresectable Stage III NSCLC
Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial